160 related articles for article (PubMed ID: 33459229)
1. GSK-3 Inhibitors: A New Class of Drugs for Alzheimer's Disease Treatment.
Pal D; Mukherjee S; Song IH; Nimse SB
Curr Drug Targets; 2021; 22(15):1725-1737. PubMed ID: 33459229
[TBL] [Abstract][Full Text] [Related]
2. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
3. GSK-3 and Tau: A Key Duet in Alzheimer's Disease.
Sayas CL; Ávila J
Cells; 2021 Mar; 10(4):. PubMed ID: 33804962
[TBL] [Abstract][Full Text] [Related]
4. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
5. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
Serenó L; Coma M; Rodríguez M; Sánchez-Ferrer P; Sánchez MB; Gich I; Agulló JM; Pérez M; Avila J; Guardia-Laguarta C; Clarimón J; Lleó A; Gómez-Isla T
Neurobiol Dis; 2009 Sep; 35(3):359-67. PubMed ID: 19523516
[TBL] [Abstract][Full Text] [Related]
6. GSK-3 inhibitors for Alzheimer's disease.
Avila J; Hernández F
Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.
Farr SA; Ripley JL; Sultana R; Zhang Z; Niehoff ML; Platt TL; Murphy MP; Morley JE; Kumar V; Butterfield DA
Free Radic Biol Med; 2014 Feb; 67():387-95. PubMed ID: 24355211
[TBL] [Abstract][Full Text] [Related]
8. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory.
Liu SJ; Zhang AH; Li HL; Wang Q; Deng HM; Netzer WJ; Xu H; Wang JZ
J Neurochem; 2003 Dec; 87(6):1333-44. PubMed ID: 14713290
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in the Discovery of GSK-3 Inhibitors from Synthetic Origin in the Treatment of Neurological Disorders.
Saha S; Pal D; Nimse SB
Curr Drug Targets; 2021; 22(12):1437-1462. PubMed ID: 33494672
[TBL] [Abstract][Full Text] [Related]
10. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.
Lovestone S; Reynolds CH; Latimer D; Davis DR; Anderton BH; Gallo JM; Hanger D; Mulot S; Marquardt B; Stabel S
Curr Biol; 1994 Dec; 4(12):1077-86. PubMed ID: 7704571
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
13. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.
Huang HC; Klein PS
Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579
[TBL] [Abstract][Full Text] [Related]
14. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
[TBL] [Abstract][Full Text] [Related]
15. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease.
Noh MY; Chun K; Kang BY; Kim H; Park JS; Lee HC; Kim YH; Ku S; Kim SH
Biochem Biophys Res Commun; 2013 May; 435(2):274-81. PubMed ID: 23632329
[TBL] [Abstract][Full Text] [Related]
16. Development of a cellular tau enzyme-linked immunosorbent assay method for screening GSK-3β inhibitors.
Cho GW; Noh MY; Kang BY; Ku IW; Park J; Hong YH; Kim MH; Kim SH
Assay Drug Dev Technol; 2011 Oct; 9(5):503-13. PubMed ID: 21561378
[TBL] [Abstract][Full Text] [Related]
17. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometry-based method to analyze the change in Tau phosphorylation in a hGSK-3beta and hTau over-expressing EcR-293 cell line.
Kurko D; Boros A; Dezso P; Urbányi Z; Sárvári M; Nagy J; Szombathelyi Z; Szendrei GI
Neurochem Int; 2006 Apr; 48(5):374-82. PubMed ID: 16420965
[TBL] [Abstract][Full Text] [Related]
19. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
20. Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β.
Amin J; Paquet C; Baker A; Asuni AA; Love S; Holmes C; Hugon J; Nicoll JA; Boche D
Neuropathol Appl Neurobiol; 2015 Jun; 41(4):445-57. PubMed ID: 25486988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
